Recent Updates
Recently added Catalysts
SNTI Positive Sentiment

First-In-Human, Multicenter Study of SENTI-202, a CD33/FLT3 Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy in Hematologic Malignancies including AML: Correlative Data

Tuesday, April 29, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a first-in-human, multicenter study of SENTI-202, a novel CAR NK cell therapy targeting CD33 and FLT3 in patients with hematologic malignancies, including acute myeloid leukemia (AML). The study aims to evaluate the therapy's effectiveness and safety, providing correlative data to support its potential use in clinical settings. This innovative approach could significantly advance treatment options in this challenging area.
Price reaction · baseline $3.64 (2025-04-28 close) · hit pre-market · 1 other SNTI headline(s) in the window, move may be shared
day 0 close · peak
-12.9%
day 1
-8.8%
day 3
-8.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • First-in-human study indicates innovative approach in CAR NK cell therapy.
  • Focus on hematologic malignancies suggests potential for significant impact.
  • Multicenter study design enhances the credibility and reach of the research.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
76.7%
average across 4 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
SENTI-202
Phase 1 · AML/MDS

Full Press Release Details

AACR Annual Meeting Muharrem Muftuoglu, Enping Hong, Stephen A. Strickland, Alireza Eghtedar, Gary Schiller, Nosha Farhadfar, Ashish R. Bajel, Farhad Ravandi, Mahesh Basyal, Li Li, Lawrence Naitmazi, Rochelle Emery,Brian S. Garrison, Timothy Lu, Kanya Rajangam, Michael Andreeff

Frequently Asked Questions

What is SENTI-202?

SENTI-202 is a CD33/FLT3 selective off-the-shelf CAR NK cell therapy.

What type of study is being conducted for SENTI-202?

A first-in-human, multicenter study is being conducted.

What malignancies does SENTI-202 target?

SENTI-202 targets hematologic malignancies, including acute myeloid leukemia.

Who are the key researchers involved in the study?

Key researchers include Muharrem Muftuoglu, Enping Hong, and Stephen A. Strickland.

ShareAdd on Google
Tags: SNTI Viatris Investor Conferences Healthcare SENTI-202 CAR NK cell therapy acute myeloid leukemia hematologic malignancies
Last updated: Apr 29, 2025

Biotech snapshot

Cash runway
$19M liquidity · $2M/mo burn
~5 mo
High dilution risk
Lead asset
SENTI-202Phase 1
AML/MDS →

Catalyst track record

+84%
best trade around SNTI's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SNTI.

See every catalyst's timing & PoA →